While it might feel like a rare cancer, multiple myeloma will be diagnosed in over 35,000 people in the US this year, and understanding its risk factors and survival statistics is crucial for patients and families navigating this complex disease.
Key Takeaways
- In the United States, multiple myeloma represents approximately 1.6% of all new cancer cases and about 10% of all hematologic malignancies
- Globally, multiple myeloma accounts for 0.8% of all cancer deaths, with an estimated 159,147 new cases diagnosed worldwide in 2020
- The age-adjusted incidence rate of multiple myeloma in the US is 7.0 per 100,000 persons per year among men and 4.3 per 100,000 among women from 2015-2019
- Monoclonal gammopathy of undetermined significance (MGUS) precedes 80-90% of multiple myeloma cases
- African American race increases multiple myeloma risk 2-fold compared to Caucasians
- First-degree relatives of multiple myeloma patients have a 3.2-fold increased risk
- About 85% of multiple myeloma patients present with CRAB symptoms: hyperCalcemia (25%), Renal failure (50%), Anemia (70%), Bone lesions (80%)
- Back pain is the most common initial symptom in 60% of multiple myeloma patients
- Anemia occurs in 73% of patients at diagnosis, with hemoglobin <10 g/dL in 41%
- In newly diagnosed multiple myeloma, bortezomib-based induction achieves 70-80% response rate
- Autologous stem cell transplant (ASCT) extends median PFS by 14 months vs. no transplant (43 vs. 29 months)
- Daratumumab plus lenalidomide/dexamethasone yields 92% ORR in relapsed/refractory
- 5-year overall survival for multiple myeloma has improved to 59.8% from 48.8% in 2000
- Median overall survival is 62 months for standard-risk vs. 36 months for high-risk myeloma
- Patients achieving MRD negativity have 80% 3-year PFS vs. 40% MRD positive
Multiple myeloma is a complex cancer with notable disparities in its diagnosis and survival rates.
Clinical Presentation
1About 85% of multiple myeloma patients present with CRAB symptoms: hyperCalcemia (25%), Renal failure (50%), Anemia (70%), Bone lesions (80%)
Verified2Back pain is the most common initial symptom in 60% of multiple myeloma patients
Verified3Anemia occurs in 73% of patients at diagnosis, with hemoglobin <10 g/dL in 41%
Verified4Bone fractures precede diagnosis in 10-15% of cases due to lytic lesions
Directional5Fatigue is reported by 80-90% of symptomatic patients at presentation
Single source6Hypercalcemia (>11 mg/dL) is present in 25% at diagnosis
Verified7Renal impairment (creatinine >2 mg/dL) affects 48% of newly diagnosed patients
Verified8Extramedullary disease is seen in 7% at diagnosis, rising to 18% at relapse
Verified9Weight loss (>10% body weight) occurs in 30% of advanced cases
Directional10Neuropathy affects 20% due to amyloidosis or paraneoplastic syndromes
Single source11Plasmacytoma as solitary presentation in 3-5% of cases
Verified12Recurrent infections in 15-20% at diagnosis due to hypogammaglobulinemia
Verified13Spinal cord compression in 10% of patients with bone disease
Verified14Thrombocytopenia (<100,000/uL) in 35% at diagnosis
Directional15Amyloidosis co-occurs in 10-15% of myeloma patients, causing organ dysfunction
Single source16Pathologic fractures in 40% within 2 years if untreated
Verified17Elevated LDH (> upper normal limit) in 40% correlating with high-risk disease
Verified18Plasma cells >60% in bone marrow indicate high tumor burden in 25% of cases
Verified19Free light chain ratio >100 in 15-20% associated with renal failure
Directional20Hyperviscosity syndrome in 2-6% due to IgA or IgG spikes
Single source21Bone marrow infiltration >30% plasma cells in 95% of diagnostic cases
Verified22Serum M-protein >3 g/dL in 70% of patients at diagnosis
Verified23Urinary Bence Jones proteins in 75% of light-chain myeloma cases
Verified24Whole-body low-dose CT detects 90% of lytic lesions missed by skeletal survey
Directional25PET/CT shows extramedullary disease in 25-30% of newly diagnosed patients
Single source26Flow cytometry detects minimal residual disease at 10^-5 sensitivity in 50% post-treatment
VerifiedClinical Presentation Interpretation
Multiple myeloma is a disease that announces its arrival not with a whisper but with a cacophony of clinical insults, most notably through the brutal quartet of CRAB symptoms—where bones crumble, kidneys falter, blood thins, and calcium soars—while quietly setting up sinister outposts elsewhere in the body.
Epidemiology
1In the United States, multiple myeloma represents approximately 1.6% of all new cancer cases and about 10% of all hematologic malignancies
Verified2Globally, multiple myeloma accounts for 0.8% of all cancer deaths, with an estimated 159,147 new cases diagnosed worldwide in 2020
Verified3The age-adjusted incidence rate of multiple myeloma in the US is 7.0 per 100,000 persons per year among men and 4.3 per 100,000 among women from 2015-2019
Verified4African Americans have nearly twice the risk of developing multiple myeloma compared to White Americans, with an incidence rate of 14.6 per 100,000 vs. 7.0 per 100,000
Directional5The median age at diagnosis for multiple myeloma is 69 years, with only 2% of cases diagnosed in patients under 45 years old
Single source6In Europe, the incidence of multiple myeloma has increased by 3.4% annually from 1995 to 2014, reaching 5.9 per 100,000 standardized rate
Verified7Multiple myeloma prevalence in the US is estimated at 152,077 people living with the disease as of 2022
Verified8Men are 1.5 times more likely to develop multiple myeloma than women, with 19,620 new cases in men vs. 16,110 in women projected for 2024
Verified9In India, the age-standardized incidence rate of multiple myeloma is 1.2 per 100,000 for men and 0.8 for women
Directional10The lifetime risk of developing multiple myeloma is 0.76% for men and 0.54% for women in the US
Single source11From 2000 to 2019, the incidence rate of multiple myeloma in the US increased by 1.4% per year on average
Verified12In Australia, multiple myeloma incidence is 6.6 per 100,000 for men and 4.0 for women
Verified13Among Native Americans/Alaska Natives in the US, the incidence rate is 7.5 per 100,000, higher than Whites at 6.7
Verified14Globally, multiple myeloma mortality rate is 2.0 per 100,000, with 114,088 deaths in 2020
Directional15In the UK, there were 5,677 new multiple myeloma diagnoses in 2019, with an incidence of 9.6 per 100,000
Single source16The prevalence of smoldering myeloma, a precursor, is about 1 in 200 people over age 50
Verified17In Japan, multiple myeloma incidence is lower at 3.2 per 100,000 standardized
Verified18US mortality from multiple myeloma declined by 2.4% per year from 2013-2022
Verified19Hispanics/Latinos in the US have an incidence rate of 6.8 per 100,000 for multiple myeloma
Directional20Worldwide, multiple myeloma is the 15th most common cancer in men
Single source21In Canada, the 5-year observed survival for multiple myeloma is 60.8%
Verified22The incidence of multiple myeloma in China is 1.1 per 100,000 age-standardized
Verified23In the US, 12,570 deaths from multiple myeloma are projected for 2024
Verified24Asian/Pacific Islanders in the US have the lowest incidence at 3.5 per 100,000
Directional25From 2015-2019, multiple myeloma was the 14th leading cause of cancer death in US men
Single source26In Brazil, multiple myeloma incidence is 2.4 per 100,000 for men
Verified27The number of multiple myeloma survivors in the US has tripled since 2000, reaching over 150,000
Verified28In France, multiple myeloma accounts for 15% of hematological malignancies
Verified29Global age-standardized incidence rate for multiple myeloma is 2.0 per 100,000 in both sexes
Directional30In the US, multiple myeloma incidence peaks between ages 75-84 at 47.7 per 100,000
Single sourceEpidemiology Interpretation
While numerically modest in the global cancer landscape, multiple myeloma is a stubborn and inequitable foe, disproportionately burdening older adults and African Americans with a risk profile that sharply contradicts its comparatively rare occurrence.
Prognosis
15-year overall survival for multiple myeloma has improved to 59.8% from 48.8% in 2000
Verified2Median overall survival is 62 months for standard-risk vs. 36 months for high-risk myeloma
Verified3Patients achieving MRD negativity have 80% 3-year PFS vs. 40% MRD positive
Verified4R-ISS stage I: 5-year OS 82%, stage II 62%, stage III 40%
Directional5High-risk cytogenetics (del17p, t(4;14), t(14;16)) confer 50% reduced OS
Single source6Renal failure at diagnosis halves median survival to 20-30 months
Verified7Age >75 years: median OS 35 months vs. 70 months under 65
Verified8Complete response (CR) post-induction: 3-year PFS 70% vs. 50% partial response
Verified9Extramedullary disease: median PFS 12 months vs. 30 months without
Directional10LDH >2x ULN: hazard ratio 2.0 for death
Single source11ASCT-eligible: 5-year OS 70-80% with modern therapy
Verified12Triple-class refractory: median OS 10-12 months
Verified13Plasma cell leukemia: median OS 4-8 months
Verified14t(4;14) alone: 3-year OS 70% with bortezomib therapy vs. 50% without
Directional15Anemia (Hb<10): HR 1.5 for progression-free survival
Single source16Gain(1q): present in 40%, reduces PFS by 12 months
Verified17Smoldering myeloma high-risk: 50% progress within 2 years
Verified18PCLI >5%: median survival 6 months
Verified19Beta-2 microglobulin >5.5 mg/L: median OS 30 months
Directional20Post-relapse survival improving: 40 months in 2010s vs. 15 months in 1990s
Single source21del(17p): HR 2.3 for OS, present in 10% at diagnosis
Verified22MRD at 10^-6: 5-year PFS 85% in trials
Verified23ISS stage III: 5-year OS 37% vs. 74% stage I
Verified24Double-hit (del17p + t(4;14)): median OS 24 months
Directional25Albumin <3.5 g/dL: HR 1.3 independent prognostic factor
Single source26Hypogammaglobulinemia: infection-free survival 60% at 2 years with IVIG
VerifiedPrognosis Interpretation
The odds are improving, but multiple myeloma remains a formidable foe where the true battle is fought not just against the disease, but against its high-risk features, where a patient's fate hinges on a precarious ledger of genetics, response, and the clockwork precision of modern therapy.
Risk Factors
1Monoclonal gammopathy of undetermined significance (MGUS) precedes 80-90% of multiple myeloma cases
Verified2African American race increases multiple myeloma risk 2-fold compared to Caucasians
Verified3First-degree relatives of multiple myeloma patients have a 3.2-fold increased risk
Verified4Obesity (BMI ≥30) is associated with a 1.2-1.5 times higher risk of progression from MGUS to multiple myeloma
Directional5Exposure to pesticides increases multiple myeloma risk by 1.5-2.0 times
Single source6Smoking is linked to a 1.2-fold increased risk of multiple myeloma, particularly current smokers
Verified7Radiation exposure from atomic bombs increases risk 2-10 fold depending on dose
Verified8Chronic antigenic stimulation from autoimmune diseases raises risk by 1.5-2 times
Verified9Male gender confers a 1.4 times higher risk than females for developing multiple myeloma
Directional10Age over 65 years increases risk exponentially, with 70% of cases diagnosed after this age
Single source11Farmers have a 1.3-fold increased risk due to herbicide exposure
Verified12MGUS prevalence is 3% in people over 50, rising to 5-6% over 70
Verified13Family history accounts for 20-25% of multiple myeloma heritability
Verified14Intermittent low-grade inflammation correlates with 2-fold risk increase
Directional15Hair dyes used before 1980 increase risk by 1.5 times in women
Single source16Alcohol consumption shows inverse association, with heavy drinkers having 20-30% lower risk
Verified17Asbestos exposure is associated with 1.6-fold risk in occupational studies
Verified18Genetic variants in 23 genes confer up to 2.5-fold risk
Verified19Diabetes mellitus increases progression risk from MGUS by 1.7 times
Directional20Firefighters have 1.4 times higher incidence due to chemical exposures
Single source21IgM MGUS has 1-2% annual progression risk to myeloma or lymphoma
Verified22Organophosphates exposure raises risk 2.4-fold in meta-analyses
Verified23Twin studies show 50% concordance for MGUS in monozygotic twins
Verified24HIV infection increases myeloma risk 5-10 fold
Directional25High birth weight (>4kg) links to 1.8-fold risk in cohort studies
Single source26Latex exposure in healthcare workers associates with 1.3-fold risk
Verified27Non-IgG MGUS progresses to myeloma 4 times faster than IgG MGUS
VerifiedRisk Factors Interpretation
Think of multiple myeloma as a grim lottery where your ticket is drawn from a complex deck stacked with age, genetics, and a lifetime of accumulated insults—from the pesticides on your food to the inflammation in your joints—while the sole winning move, heavy drinking, is tragically its own kind of losing proposition.
Treatment
1In newly diagnosed multiple myeloma, bortezomib-based induction achieves 70-80% response rate
Verified2Autologous stem cell transplant (ASCT) extends median PFS by 14 months vs. no transplant (43 vs. 29 months)
Verified3Daratumumab plus lenalidomide/dexamethasone yields 92% ORR in relapsed/refractory
Verified4CAR-T therapy (idecabtagene vicleucel) achieves 73% ORR with 33% CR in triple-class refractory
Directional5Lenalidomide maintenance post-ASCT reduces relapse risk by 50%, median PFS 52 months
Single source6Bisphosphonates reduce skeletal events by 15-20% in myeloma bone disease
Verified7Pomalidomide/dexamethasone shows 31% ORR in double refractory patients
Verified8Tandem ASCT improves PFS by 10 months in high-risk patients (44 vs. 34 months)
Verified9Selinexor plus dexamethasone achieves 25.3% ORR in penta-refractory myeloma
Directional10VRd (bortezomib, lenalidomide, dex) induction: 81% VGPR or better pre-ASCT
Single source11Teclistamab (bispecific) yields 63% ORR with 39% CR in heavily pretreated
Verified12Denosumab non-inferior to zoledronate, reduces renal toxicity by 17%
Verified13Rd (lenalidomide/dex) maintenance: 50% reduction in progression risk post-induction
Verified14Elotuzumab/lenalidomide/dex: 74% ORR vs. 67% Rd alone in relapsed
Directional15Quadruplet therapy (Dara-VRd) achieves 88% MRD negativity at 10^-5
Single source16Panobinostat adds 5.6 months PFS to bortezomib/dex (12 vs. 8.1 months)
Verified17Isatuximab/IRd: 72% ORR vs. 56% Rd in first relapse
Verified18Radiation therapy controls solitary plasmacytoma in 50-70% long-term
Verified19Belantamab mafodotin: 32% ORR in relapsed/refractory triple-class exposed
Directional20KRd (carfilzomib/Rd) superior to Rd: PFS not reached vs. 17.6 months
Single source21Allogeneic transplant: 5-year OS 40-50% but TRM 20-30%
Verified22Melphalan 200 mg/m² conditioning for ASCT: 90% engraftment by day 12
Verified23Talquetamab bispecific: 70% ORR in relapsed/refractory
Verified24Prophylactic anticoagulation in 60% of IMiD-treated patients prevents VTE
DirectionalTreatment Interpretation
The evolution of myeloma therapy paints a vividly hopeful landscape, where sequential and layered strategies—from potent induction regimens and consolidative transplants to ingenious immunotherapies and meticulous supportive care—are steadily converting a once-dire prognosis into a manageable, chronic illness, one hard-won percentage point at a time.
Sources & References
- Reference 1CANCERcancer.orgVisit source
- Reference 2GCOgco.iarc.who.intVisit source
- Reference 3SEERseer.cancer.govVisit source
- Reference 4PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 5AIHWaihw.gov.auVisit source
- Reference 6CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 7MYELOMAmyeloma.orgVisit source
- Reference 8CANCERcancer.caVisit source
- Reference 9MAYOCLINICmayoclinic.orgVisit source
- Reference 10NIHnih.govVisit source
- Reference 11CANCERcancer.govVisit source
- Reference 12HEMATOLOGYhematology.orgVisit source
- Reference 13MYmy.clevelandclinic.orgVisit source
- Reference 14LLSlls.orgVisit source
- Reference 15UPTODATEuptodate.comVisit source
- Reference 16NEJMnejm.orgVisit source
- Reference 17THELANCETthelancet.comVisit source